

I-LID 'N LASH® PLUS: A SAFE AND EFFECTIVE PRODUCT IN MANAGING DEMODICOSIS IN VIVO

Prospective multi-centered study conducted by: Shaun MacInnis and Aleem Bandali

AIM OF THE STUDY

- 1. To prove the **efficacy** of I-LID 'N LASH[®] PLUS containing 5% tea tree oil in managing Demodicosis by reducing the collarettes/cylindrical dandruff counts and improving tear film stability.
- 2. To prove the **safety** of 5% tea tree oil on the Meibomian glands, *in vivo*.



BACKGROUND


- The study included 21 patients (nine males and twelve females), with an average age of 70 years old (38 to 93 years old) with confirmed demodicosis.
 Patients underwent 30 to 45 days of treatment by using I-LID 'N LASH[®] PLUS
- twice daily while maintaining their regular treatment for other conditions.
- Patients with known allergies to any of the I-LID 'N LASH[®] PLUS ingredients were not enrolled in the study.

RESULTS ANALYSIS

COLLARETTES SEVERITY SCALE


The collarettes severity scale refers to the total number of collarettes/cylindrical dandruff per 10 eyelashes following the table below:

Item	Score (collarettes per 10 eyelid lashes)			
Eyelid collarettes	None = 0	Mild = 1-3	Moderate = 4-6	Severe = 7-10



COLLARETTES SEVERITY SCORE

Results showed the reduction in the collarettes severity where patients shifted from Moderate and Severe severity grades to None or Mild.



OSDI Score

NITBUT

ns 29.1%

RIGHT EVE AFTER

BEFORE

6.53

13.9%

LEFT FYE BEFOR

AFTER

Meibography (percentage area lost)

AVERAGE COLLARETTES SCORE

Results demonstrate a significant (p=0,00009, ***) 42% reduction of Average Collarettes Score in the whole set of patients.

[†] In a subgroup comprised of participants under 60 years old, the results showed a significant (p= 0.006, ***) 60% reduction in Average Collarettes Score.

OSDI QUESTIONNAIRE

This improvement in demodicosis was accompanied by a significant (p=0.001, ***) 57% improvement in overall symptomatology, seen by a decrease in OSDI Score.

[†] In a subgroup comprised of participants under 60 years old, improvement in demodicosis was reflected in a significant (p=0.007, ***) 73% improvement in overall symptomatology, seen by a decrease in OSDI Score.

NITBUT

Another improvement was noticed in the tear stability seen by a non-significant increase in Tear Break-Up time, proposing that improving demodicosis contributed to improving overall tear film stability even while other underlying conditions are being treated separately.

MEIBOGRAPHY

The study data also confirmed the safety of **I-LID** '**N LASH**[®] **PLUS** on the viability of the Meibomian gland. The study demonstrated that after 30 to 45 days of use, twice daily, there is no significant increase in the percentage area lost as seen in the graph.

CONCLUSION

20

15

10

5

30

25

20

15

10

PERCENTAGE AREA LOST

NITBUT (IN SECONDS)

This study demonstrates the positive effect of **I-LID** '**N LASH**[®] **PLUS** on improving demodicosis. It also showed that improving demodicosis will have a positive impact on dry eye, thus it is a core step in comprehensive dry eye management. The results also demonstrated that **I-LID** '**N LASH**[®] **PLUS** has no harmful effect on the Meibomian Gland integrity as seen by the meibography.